StockNews.com Upgrades MediWound (NASDAQ:MDWD) to Sell

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a research report sent to investors on Friday.

Several other research analysts also recently commented on the stock. Craig Hallum assumed coverage on shares of MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of MediWound in a research report on Thursday.

MediWound Price Performance

Shares of MDWD stock opened at $16.27 on Friday. The company has a market cap of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82. The firm has a 50-day moving average of $18.17 and a 200-day moving average of $17.59. MediWound has a one year low of $12.78 and a one year high of $24.00.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. During the same quarter last year, the business earned ($0.19) earnings per share. As a group, research analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in shares of MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 45,529 shares during the last quarter. Barclays PLC grew its stake in shares of MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 8,449 shares during the last quarter. Rhumbline Advisers grew its stake in shares of MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 739 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of MediWound during the third quarter worth about $212,000. Finally, Essex Investment Management Co. LLC lifted its holdings in MediWound by 30.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after acquiring an additional 35,012 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.